The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1238
July 3, 2006
View Complete Issue         Table of Contents 2019 
A Betamethasone-Calcipotriene Combination for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Betamethasone-Calcipotriene Combination for Psoriasis
July 3, 2006 (Issue: 1238)
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Betamethasone-Calcipotriene Combination for Psoriasis
Article code: 1238c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.